References
- Dansette PM, Bertho G, Mansuy D. First evidence that cytochrome P450 may catalyse both S-oxidation and epoxidation of thiophene derivatives. Biochemical and Biophysical Research Communications 2005; 338: 450–455
- Emoto C, Iwasaki K. Enzymatic characteristics of CYP3A5 and CYP3A4: A comparison of in vitro kinetic and drug–drug interaction patterns. Xenobiotica 2006; 36: 219–233
- Guengerich FP. Human cytochrome P450 enzymes. Cytochrome P450, PR Oritiz de Montellano. Plenum, New York, NY 1995; 473–535
- Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Reviews in Pharmacology and Toxicology 1999; 39: 1–17
- Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, Mansuy D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 2001; 40: 12112–12122
- Houston JB, Kenworthy KE. In vitro–in vivo scaling of CYP kinetic data not consistent with the classical Michaelis–Menten model. Drug Metabolism and Disposition 2000; 28: 246–254
- Isin EM, Guengerich FP. Complex reactions catalysed by cytochrome P450 enzymes. Biochimica et Biophysica Acta 2006; 1770: 314–329
- Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clinical Pharmacokinetics Concepts 1994; 26: 144–160
- Lewis DF, Eddershaw PJ, Goldfarb PS, Tarbit MH. Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica 1996; 26: 1067–1086
- Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1–42
- Rendic S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metabolism Reviews 2002; 34: 83–448
- Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, Korzekwa KR. Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994; 33: 6450–6455
- Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews 1995; 27: 397–417
- Stadler R, Zenk MH. The purification and characterization of a unique cytochrome P-450 enzyme from Berberis stolonifera plant cell cultures. Journal of Biological Chemistry 1993; 268: 823–831
- Suzuki H, Kneller MB, Haining RL, Trager WF, Rettie AE. (+)-N-3-benzyl-nirvanol and (–)-N-3-benzyl-phenobarbital: New potent and selective in vitro inhibitors of CYP2C19. Drug Metabolism and Disposition 2002; 30: 235–239
- Zhao B, Guengerich FP, Bellamine A, Lamb DC, Izumikawa M, Lei L, Podust LM, Sundaramoorthy M, Kalaitzis JA, Reddy LM, et al. Binding of two flaviolin substrate molecules, oxidative coupling, and crystal structure of Streptomyces coelicolor A3(2) cytochrome P450 158A2. Journal of Biological Chemistry 2005; 280: 11599–11607
- Zhuo M. Glutamate receptors and persistent pain: Targeting forebrain NR2B subunits. Drug Discovery Today 2002; 7: 259–267